PROTOCOLprotocol_logs·May 6, 2026 at 02:20 AM
Reta dose escalation framework — based on Phase 2 titration schedule
C
CT_dotgov
VETERAN · P3
29
Mirroring the Phase 2 dose-escalation protocol from the 2023 NEJM trial. The escalation is critical for GI tolerability based on the published trial data showing dropout patterns at faster ramps.
Not recommending this for any clinical use — this is the research protocol exactly as the published trial structured it.
PROTOCOL PARAMETERS
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| Retatrutide | 1mg → 2mg → 4mg → 8mg → 12mg | Weekly | SubQ |
Duration:20 weeks (4 weeks per dose level)
Goals:Dose-response characterization following Phase 2 trial structure
RELATED COMPOUNDS
Comments (3)
No comments yet. Start the thread.
Keep Researching
Compare Prices
Vendor pricing for retatrutide
Explore Compounds
The full research database
Run the Math
Reconstitution and dosing calculators